Blood Immunology & Cellular Therapy
Publisher: Elsevier · ISSN 3050-5976 · 52 articles
- Impact of Delayed Infusion on Safety and Efficacy of Anti-CD19 and Anti-BCMA CAR T-Cell Therapies
- Single-cell T-cell secretome assay captures T-cell fitness in myeloma patients receiving T-cell redirection therapies
- Outcomes of patients with primary refractory and early relapsing large B-cell lymphoma are inferior in the CD19 CAR T era
- BCMA-targeted T-cell engager therapy induces sustained remission in immune thrombocytopenia
- Disparity in access to multiple myeloma CAR-T: a geospatial analysis of distance to CAR-T centers
- Glucocorticoid-induced TNF receptor ligand–dependent B-cell expansion of regulatory T cells as an immune cell therapy strategy
- Cytoreduction with bridging therapy improves outcomes after CD19 CAR T-cell therapy in B-ALL with high disease burden
- Preleukapheresis risk factors for BCMA CAR-T product manufacturing failure
- Acute myeloid leukemia cell therapy by combining MR1-modulating drugs and MR1 T cells
- Referral variability and provider preparedness for pediatric sickle cell gene therapy: a national survey
- Prospective cohort study of immunosuppression taper and discontinuation after allogeneic stem cell transplantation
- Antigen levels in normal B cells and B-cell malignancies established by a multicolor quantitative flow cytometry assay
- Accelerated step-up dosing of glofitamab in rapidly progressive R/R DLBCL: a real-world cohort analysis
- Immunological rationale for PD-1 blockade in intravascular large B-cell lymphoma harboring a PD-L1 structural variant
- B7-H3 expression affects outcomes in myeloma and is targetable with an NK cell engager
- Real-world outcomes of glofitamab therapy in CAR-T–naïve patients with relapsed/refractory large B-cell lymphoma
- Real-world outcomes of tafasitamab-lenalidomide in patients with transplant-ineligible R/R DLBCL from the PRO-MIND study
- Targeting CD52 provides durable depletion of circulating CAR T cells in a patient with BCMA-CAR T-cell–associated parkinsonism
- Filioglou D, Simpson RJ, Katsanis E. Donor lymphocyte infusion as immune modulation after pediatric allogeneic transplantation. Blood Immunol Cell Ther. 2026;2(2):100055.
- Costa BA, Tan CR, Shekarkhand T, et al. Practical use of talquetamab in relapsed/refractory multiple myeloma: the Memorial Sloan Kettering Cancer Center experience. Blood Immunol Cell Ther. 2025;1(2):100005.
- Bariana M, Anand S, Batistick M, et al. Combining antigen-specific T cells with T-cell engager therapy induces a molecular signature that favors T-cell fitness. Blood Immunol Cell Ther. 2025;1(1):100002.
- Zhang Q, Wu Y, Yang J, et al. Viral vector-free generation of orthogonal IL-2–responsive CAR T cells through gene editing of IL-2 and its receptor. Blood Immunol Cell Ther. 2025;1(3):100019.
- Does size matter? Impact Of Body Mass Index On Outcome Of Anti-CD19 CAR-T Cell Therapy For B-Cell Lymphoma
- Chimeric antigen receptor T-cell transgene identity, site and methylation analysis via long-read sequencing
- T-cell receptors targeting distinct FLT3-D835Y neoantigens display differential reactivity toward acute myeloid leukemia
- NK cell immunosurveillance and CX3CL1-CX3CR1 axis perturbations in ETV6::RUNX1 positive preleukemia and BCP-ALL
- Complementary immunomodulatory effects of talquetamab plus daratumumab with or without pomalidomide in multiple myeloma
- Bispectral Electroencephalography for Detection and Monitoring of ICANS After CAR T-Cell Therapy
- EFFICACY AND SAFETY OF ANTI-CD19 CAR T-CELL THERAPY IN SECONDARY CNS LYMPHOMAS REFRACTORY TO HIGH-DOSE METHOTREXATE-BASED TREATMENT
- Real-world experience of anakinra prophylaxis in CAR-T